KRAS and familial pancreatic carcinoma: As a preclinic drug, ARS-1620 has been also reported to disrupt the association between KRAS and Argonaute two on the plasma membrane, which may bring the therapeutic feasibility for pancreatic cancer (Shankar et al., 2020).